New data for Menveo vaccine show excellent immune response and broad protection for infants against meningococcal meningitis
Menveo (MenACWY-CRM) the first quadrivalent conjugated meningitis vaccine to demonstrate an excellent immune response in infants
16-Nov-2007 -
New clinical data for the Novartis development vaccine Menveo(TM) (MenACWY-CRM) show an excellent and broad immune response in infants as young as six months of age against four common serogroups (or types) of meningococcal meningitis, a potentially fatal bacterial disease involving inflammation ...
AGES
bacterial diseases
clinical trials
+8